Effect and Mechanism of Probiotics in Alleviating or Treating Inflammatory Bowel Disease

XU Kang; WANG Zhe; XUE Zhipeng; WANG Jiapeng; XU Zhenshang; WANG Ting

doi:10.13386/j.issn1002-0306.2021090166

Volume 43 Issue 20

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2022 > 43(20): 414-420. > DOI: 10.13386/j.issn1002-0306.2021090166

XU Kang, WANG Zhe, XUE Zhipeng, et al. Effect and Mechanism of Probiotics in Alleviating or Treating Inflammatory Bowel Disease[J]. Science and Technology of Food Industry, 2022, 43(20): 414−420. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2021090166.

Citation:

PDF (2021 KB)

Effect and Mechanism of Probiotics in Alleviating or Treating Inflammatory Bowel Disease

School of Biological Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China

More Information

Received Date: September 13, 2021
Available Online: August 03, 2022

Graphical Abstract

Abstract

Abstract

Inflammatory bowel disease (IBD), gradually increasing in China, is a chronic and recurrent intestinal inflammatory disease. Recently, probiotics have been applied for the treatment of IBD, and some probiotic strains can alleviate or treat IBD by protection of the intestinal barrier and regulating expression of immune and inflammatory factors. Meanwhile, probiotics have the characteristics of good tolerability and few adverse reactions, resulting in their commonness in the clinical application of IBD treatment. This article mainly introduces the research progress of probiotics in the treatment of IBD, including the classification, mechanism of action and clinical research.
- probiotics,
- inflammatory bowel disease(IBD),
- mechanism,
- clinical research

FullText(HTML)

References (50)

References

[1]	ZHANG Y Z, LI Y Y. Inflammatory bowel disease: Pathogenesis[J]. World Journal of Gastroenterology,2014,20(1):91−99. doi: 10.3748/wjg.v20.i1.91
[2]	NA S Y, MOON W. Perspectives on current and novel treatments for inflammatory bowel disease[J]. Gut and Liver,2019,13(6):604−616. doi: 10.5009/gnl19019
[3]	HILL C, GUARNER F, REID G, et al. Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nature Reviews Gastroenterology & Hepatology,2014,11(8):506−514.
[4]	BOIRIVANT M, STROBER W. The mechanism of action of probiotics[J]. Current Opinion in Gastroenterology,2007,23(6):679−692. doi: 10.1097/MOG.0b013e3282f0cffc
[5]	GUANDALINI S, SANSOTTA N. Probiotics in the treatment of inflammatory bowel disease[J]. Advances in Experimental Medicine and Biology,2019,1125:101−107.
[6]	LIU Y W, SU Y W, ONG W K, et al. Oral administration of Lactobacillus plantarum K68 ameliorates DSS-induced ulcerative colitis in BALB/c mice via the anti-inflammatory and immunomodulatory activities[J]. International Immunopharmacology,2011,11(12):2159−2166. doi: 10.1016/j.intimp.2011.09.013
[7]	SUN M, LIU Y, SONG Y, et al. The ameliorative effect of Lactobacillus plantarum-12 on DSS-induced murine colitis[J]. Food & Function,2020,11(6):5205−5222.
[8]	CHUNG Y W, CHOI J H, OH T Y, et al. Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice[J]. Clinical and Experimental Immunology,2008,151(1):182−189.
[9]	GHASEMI-NIRI S F, ABDOLGHAFFARI A H, FALLAH-BENAKOHAL S, et al. On the benefit of whey-cultured Lactobacillus casei in murine colitis[J]. Journal of Physiology and Pharmacology,2011,62(3):341−346.
[10]	CHEN C L, HSU P Y, PAN T M. Therapeutic effects of Lactobacillus paracasei subsp.paracasei NTU 101 powder on dextran sulfate sodium-induced colitis in mice[J]. Journal of Food and Drug Analysis,2019,27(1):83−92. doi: 10.1016/j.jfda.2018.05.004
[11]	SCHREIBER O, PETERSSON J, PHILLIPSON M, et al. Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte- and platelet-endothelial cell interactions[J]. American Journal of Physiology Gastrointestinal and Liver Physiology,2009,296(3):G534−G542. doi: 10.1152/ajpgi.90470.2008
[12]	MIYAUCHI E, MORITA H, TANABE S. Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo[J]. Journal of Dairy Science,2009,92(6):2400−2408. doi: 10.3168/jds.2008-1698
[13]	JO S G, NOH E J, LEE J Y, et al. Lactobacillus curvatus WiKim38 isolated from kimchi induces IL-10 production in dendritic cells and alleviates DSS-induced colitis in mice[J]. Journal of Microbiology,2016,54(7):503−509. doi: 10.1007/s12275-016-6160-2
[14]	CHAUHAN R, VASANTHAKUMARI A S, PANWAR H, et al. Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1[J]. BioMed Research International,2014,2014(3):206732.
[15]	IZUMI H, MINEGISHI M, SATO Y, et al. Bifidobacterium breve alters immune function and ameliorates DSS-induced inflammation in weanling rats[J]. Pediatric Research,2015,78(4):407−416. doi: 10.1038/pr.2015.115
[16]	SRUTKOVA D, SCHWARZER M, HUDCOVIC T, et al. Bifidobacterium longum CCM 7952 promotes epithelial barrier function and prevents acute DSS-induced colitis in strictly strain-specific manner[J]. PloS One,2015,10(7):e0134050. doi: 10.1371/journal.pone.0134050
[17]	MIYAUCHI E, OGITA T, MIYAMOTO J, et al. Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response: Involvement of intestinal epithelial costimulatory molecules[J]. PloS one,2013,8(11):e79735. doi: 10.1371/journal.pone.0079735
[18]	OGITA T, NAKASHIMA M, MORITA H, et al. Streptococcus thermophilus ST28 ameliorates colitis in mice partially by suppression of inflammatory Th17 cells[J]. Journal of biomedicine & biotechnology,2011,2011:378417.
[19]	BAILEY J R, VINCE V, WILLIAMS N A, et al. Streptococcus thermophilus NCIMB 41856 ameliorates signs of colitis in an animal model of inflammatory bowel disease[J]. Beneficial microbes,2017,8(4):605−614. doi: 10.3920/BM2016.0110
[20]	CHEN Y, ZHANG M, REN F. A Role of exopolysaccharide produced by Streptococcus thermophilus in the intestinal inflammation and mucosal barrier in Caco-2 monolayer and dextran sulphate sodium-induced experimental murine colitis[J]. Molecules,2019,24(3):513. doi: 10.3390/molecules24030513
[21]	IM E, CHOI Y J, POTHOULAKIS C, et al. Bacillus polyfermenticus ameliorates colonic inflammation by promoting cytoprotective effects in colitic mice[J]. The Journal of Nutrition,2009,139(10):1848−1854. doi: 10.3945/jn.109.108613
[22]	ZHANG H L, LI W S, XU D N, et al. Mucosa-reparing and microbiota-balancing therapeutic effect of Bacillus subtilis alleviates dextrate sulfate sodium-induced ulcerative colitis in mice[J]. Experimental and Therapeutic Medicine,2016,12(4):2554−2562. doi: 10.3892/etm.2016.3686
[23]	CAO G T, WANG K L, LI Z M, et al. Bacillus amyloliquefaciens ameliorates dextran sulfate sodium-induced colitis by improving gut microbial dysbiosis in mice model[J]. Frontiers in Microbiology,2019,9:3260. doi: 10.3389/fmicb.2018.03260
[24]	KANDA T, NISHIDA A, OHNO M, et al. Enterococcus durans TN-3 induces regulatory T cells and suppresses the development of dextran sulfate sodium (DSS)-induced experimental colitis[J]. PloS One,2016,11(7):e0159705. doi: 10.1371/journal.pone.0159705
[25]	CHOI E J, LEE H J, KIM W J, et al. Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model[J]. PloS One,2019,14(2):e0210854. doi: 10.1371/journal.pone.0210854
[26]	SOUZA É L, ELIAN S D, PAULA L M, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model[J]. Journal of Medical Microbiology,2016,65(3):201−210. doi: 10.1099/jmm.0.000222
[27]	LU J B, DONG B Y, CHEN A L, et al. Escherichia coli promotes DSS-induced murine colitis recovery through activation of the TLR4/NF-κB signaling pathway[J]. Molecular Medicine Reports,2019,19(3):2021−2028.
[28]	ZHANG M M, QIU X Y, ZHANG H, et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats[J]. PloS One,2014,9(10):e109146. doi: 10.1371/journal.pone.0109146
[29]	GANJI-ARJENAKI M, RAFIEIAN-KOPAEI M. Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review[J]. Journal of Cellular Physiology,2018,233(3):2091−2103. doi: 10.1002/jcp.25911
[30]	REMBACKEN B J, SNELLING A M, HAWKEY P M, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial[J]. Lancet,1999,354(9179):635−639. doi: 10.1016/S0140-6736(98)06343-0
[31]	TAMAKI H, NAKASE H, INOUE S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial[J]. Digestive Endoscopy:Official Journal of the Japan Gastroenterological Endoscopy Society,2016,28(1):67−74.
[32]	ZOCCO M A, DAL VERME L Z, CREMONINI F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis[J]. Alimentary Pharmacology & Therapeutics,2006,23(11):1567−1574.
[33]	OLIVA S, DI NARDO G, FERRARI F, et al. Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis[J]. Alimentary Pharmacology & Therapeutics,2012,35(3):327−334.
[34]	SOOD A, MIDHA V, MAKHARIA G K, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis[J]. Clinical Gastroenterology and Hepatology,2009,7(11):1202−1209. doi: 10.1016/j.cgh.2009.07.016
[35]	ISHIKAWA H, AKEDO I, UMESAKI Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis[J]. Journal of the American College of Nutrition,2003,22(1):56−63. doi: 10.1080/07315724.2003.10719276
[36]	BOUSVAROS A, GUANDALINI S, BALDASSANO R N, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease[J]. Inflammatory Bowel Diseases,2005,11(9):833−839. doi: 10.1097/01.MIB.0000175905.00212.2c
[37]	BOURREILLE A, CADIOT G, LE DREAU G, et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease[J]. Clinical gastroenterology and hepatology:The Official Clinical Practice Journal of the American Gastroenterological Association,2013,11(8):982−987. doi: 10.1016/j.cgh.2013.02.021
[38]	MARTEAU P, LéMANN M, SEKSIK P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial[J]. Gut,2006,55(6):842−847. doi: 10.1136/gut.2005.076604
[39]	LIU X J, YU R, ZOU K F. Probiotic mixture VSL#3 alleviates dextran sulfate sodium-induced colitis in mice by downregulating T follicular helper cells[J]. Current medical science,2019,39(3):371−378. doi: 10.1007/s11596-019-2045-z
[40]	TOUMI R, ABDELOUHAB K, RAFA H, et al. Beneficial role of the probiotic mixture ultrabiotique on maintaining the integrity of intestinal mucosal barrier in DSS-induced experimental colitis[J]. Immunopharmacology and immunotoxicology,2013,35(3):403−409. doi: 10.3109/08923973.2013.790413
[41]	王彦博. 功能各异的益生菌复合缓解DSS诱导的溃疡性结肠炎机制研究 [D]. 吉林: 吉林大学, 2020. WANG Y B. Study on the mechanism of compound probiotics with different functions to relieve DSS-induced ulcerative colitis[D]. Jilin: Jilin University, 2020.
[42]	YOSHIMATSU Y, YAMADA A, FURUKAWA R, et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis[J]. World Journal of Gastroenterology,2015,21(19):5985−5994. doi: 10.3748/wjg.v21.i19.5985
[43]	SARAO L K, ARORA M. Probiotics, prebiotics, and microencapsulation: A review[J]. Critical Reviews in Food Science and Nutrition,2017,57(2):344−371. doi: 10.1080/10408398.2014.887055
[44]	李东尧. 低聚糖对肠道轴向微生物代谢功能的影响及机制 [D]. 无锡: 江南大学, 2020. LI D Y. The effect and mechanism of oligosaccharides on intestinal axial microbial metabolism[D]. Wuxi: Jiangnan University, 2020.
[45]	WASILEWSKI A, ZIELIŃSKA M, STORR M, et al. Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease[J]. Inflammatory bowel diseases,2015,21(7):1674−1682. doi: 10.1097/MIB.0000000000000364
[46]	HIJOVÁ E, ŠOLTÉSOVÁ A, SALAJ R, et al. Preventive use of Lactobacillus plantarum LS/07 and inulin to relieve symptoms of acute colitis[J]. Acta Biochimica Polonica,2015,62(3):553−557. doi: 10.18388/abp.2015_1008
[47]	王亚楠, 孟祥辰, 王春赛尔, 等. 益生菌和合生元对急性结肠炎小鼠肠道炎症及微生物群的影响[J]. 中华内科杂志,2019,58(8):584−591. [WANG Y N, MENG X C, WANG C S E, et al. The influence of probiotics and synbiotics on intestinal inflammation and microbiota in mice with acute colitis[J]. Zhonghua Nei Ke Za Zhi,2019,58(8):584−591.
[48]	ISHIKAWA H, MATSUMOTO S, OHASHI Y, et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: A randomized controlled study[J]. Digestion,2011,84(2):128−133. doi: 10.1159/000322977
[49]	FUJIMORI S, GUDIS K, MITSUI K, et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis[J]. Nutrition,2009,25(5):520−525. doi: 10.1016/j.nut.2008.11.017
[50]	郭宇冰, 王晓娜, 刘欣, 等. 肠道菌群与炎症性肠病关系的研究现状[J]. 结直肠肛门外科,2020,26(4):402−406,422. [GUO Yubing, WANG Xiaona, LIU Xin, et al. Research status of the relationship between intestinal flora and inflammatory bowel disease[J]. Colorectal and Anal Surgery,2020,26(4):402−406,422. doi: 10.19668/j.cnki.issn1674-0491.2020.04.003

Supplements (0)

Cited By

Cited by

Periodical cited type(12)

1.	林柳雁，王丽，萧绮莉，蒋小红，陈惠冰. 成人炎症性肠病患者经口营养管理的证据总结. 护理实践与研究. 2025(02): 244-251 .
2.	雷露，吕沛然，张宁，梁越，赵耀，赵娴. 中医治疗炎症性肠病机制的研究进展. 中医药学报. 2024(02): 116-121 .
3.	李振，崔艳红，刘长忠，袁梦. 枯草芽孢杆菌对环境耐受性和产中性蛋白酶能力研究. 黑龙江畜牧兽医. 2024(04): 81-87+92 .
4.	耿英杰，戚浩龙，李园，蔡晓青. 益生菌治疗炎症性肠病的研究进展. 中国医药工业杂志. 2024(08): 1069-1077 .
5.	李文，刘夫锋. 基于益生菌口服药物递送系统的研究进展. 微生物学报. 2024(11): 4086-4105 .
6.	曾馨苑，吴严玮. 益生菌联合复方谷氨酰胺和马来酸曲美布汀治疗腹泻型肠易激综合征的疗效观察. 中国处方药. 2024(11): 105-107 .
7.	乌云，浩斯，巴达玛斯仁，锡林其其格，斯琴. 蒙医大肠宝如病与炎症性肠病的相关研究进展. 中国民族医药杂志. 2023(01): 65-67 .
8.	王秋珍，邓自腾，兰静，刘雪连，范祥伟，薛毅，马云飞. 干酪乳杆菌对DSS诱导结肠炎小鼠焦虑样行为的影响及对结肠的保护作用. 中国农业大学学报. 2023(04): 139-146 .
9.	杨硕，唐宗馨，段勃帆，陈禹含，郭欢新，孟祥晨. 双歧杆菌及其制剂对炎症性肠病作用机制研究进展. 食品科学. 2023(05): 275-281 .
10.	侯保秋，董怡文，刘方. 一株分离自牦牛乳中的副干酪乳杆菌ZZ102对溃疡性结肠炎的缓解作用研究. 中国乳品工业. 2023(10): 21-25 .
11.	刘柘君，刘振权，孙文燕. 复方益生菌粉提高小鼠免疫力的实验研究. 食品与药品. 2023(05): 456-461 .
12.	杨敏琪，张吉翔，董卫国. 益生菌治疗炎性肠病的研究进展. 疑难病杂志. 2022(11): 1202-1205 .